|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
It would be of great importance to better understand SGLT2 inhibitor mechanisms of action since they could have a potential to be used in early stages of diabetes as cardioprotective agents.
|
31410757 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The sodium glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin is a novel drug for the treatment of diabetes mellitus.
|
30559106 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Sodium glucose cotransporter-2 inhibitors (SGLT2i) exert cardiorenal protection in people with diabetes.
|
31641524 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Reports that sodium glucose cotransporter 2 inhibitors decrease cardiovascular death and events in patients with diabetes have attracted attention in the cardiology field.
|
31167663 |
2019 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Are SGLT2 polymorphisms linked to diabetes mellitus and cardiovascular disease? Prospective study and meta-analysis.
|
30988077 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
There is growing evidence from Phase III randomized clinical trials of the cardiovascular benefits of sodium glucose cotransporter 2 (SGLT2) inhibitors in patients with diabetes mellitus.
|
30475996 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1 Receptor Agonists (GLP-1R) and sodium glucose cotransporter-2 inhibitors are suggested as the first line towards fighting all DM, CVD and ESRD.
|
31261624 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Glucose reabsorption in the proximal tubule (via Sglt1 and Sglt2) has emerged as an important contributor to the development of diabetes.
|
30484350 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>Sglt1</i> (also known as <i>Slc5a1</i>) and <i>Sglt2</i> (also known as <i>Slc5a2</i>) knockout mice were employed to develop sotagliflozin, a dual SGLT1/SGLT2 inhibitor having success in clinical trials for diabetes.
|
31064765 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
SGLT2 inhibitors and the changing landscape for treatment of diabetes.
|
31371973 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The Q-Finder algorithm identified four clinically relevant subgroups showing superior RFP with SGLT2 inhibitors (P < 0.1): no hyperlipidaemia and eGFR ≥79 mL/min/1.73 m<sup>2</sup> ; eGFR ≥79 mL/min/1.73 m<sup>2</sup> and diabetes duration ≤1.2 years; eGFR ≥75 mL/min/1.73 m<sup>2</sup> and use of antithrombotic agents; and haemoglobin ≤13.4 g/dL and LDL cholesterol ≥95.1 mg/dL.
|
31050099 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
This review comprises a summary of patent applications (2013-2018) of SGLT2 inhibitors with focus on chemical structural advancement and therapeutic potentials in the management of diabetes and related disorders.
|
31026402 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The overview sums up the approaches implicated by the study that can potentially counteract the detrimental impact of hyperglycemia on vascular function in people with diabetes, including the clinical use of SGLT2 inhibitors for those with type 2 diabetes already being treated, for example, with metformin, along with dietary supplementation with broccoli-derived sulforaphane and tetrahydrobiopterin.
|
30930073 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Very recent treatment strategies include the PCSK9 inhibitors for hypercholesterolaemia and the SGLT2 inhibitors for reduction of cardiovascular events in patients with diabetes mellitus and increased cardiovascular risk.
|
30338502 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
SGLT2 inhibition might also be useful in the treatment of gout and gouty arthritis, especially when co-existent with diabetes.
|
30762288 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
We report data on the use of SGLT2 inhibitors in a case series of ten patients with diabetes after kidney transplantation in order to analyze efficacy, safety, and the effect on renal function.
|
31437852 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
SGLT2 inhibitors are being actively studied in the treatment of patients with HF, including in those without diabetes mellitus.
|
30704605 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
In this work, aiming at finding a novel, potent, and selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor with good pharmacokinetic profiles for the treatment of diabetes, we focus on modifying the sugar moiety of SGLT2 inhibitors, which dominates the binding with glucose binding site of hSGLT, via removing the C-6 hydroxy group to adjust the physicochemical properties and target-recognition manners of SGLT2 inhibitors.
|
31325786 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
One consequence of these findings has been greater attention to fracture outcomes in trails of new diabetes medication (incretins and SGLT-2 inhibitors).
|
31842574 |
2019 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes.
|
31359514 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Herein, we advocated the vital role of natural products as source of new drugs by presenting promising inhibitors of dipeptidyle peptidase-4 enzyme, α-glucosidase enzyme and (SGLT2) obtained from different medicinal plants as potential candidates for drug development against diabetes mellitus.
|
30738330 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Such SGLT2 inhibitors exert favourable effects in experimental models of HFpEF and have been found in large-scale trials to reduce the risk for serious heart failure events in patients with type 2 diabetes, many of whom were retrospectively identified as having HFpEF.
|
31523904 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
These observations raise the possibility that SGLT2 inhibitors could reduce morbidity and mortality in patients with established heart failure, including those without diabetes.
|
31584231 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are drugs for diabetes and might prevent heart failure.
|
31105148 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
In this mouse model of diabetes and NASH/HCC, canagliflozin showed anti-steatotic and anti-inflammatory effects that attenuated the development of NASH and prevented the progression of NASH to HCC, partly due to the induction of cell cycle arrest and/or apoptosis as well as the reduction of tumor growth through the direct inhibition of SGLT2 in tumor cells.
|
31652578 |
2019 |